UNSPSC 51271902: Ambucaine

This classification denotes an anesthetic agent with the molecular formula C17H28N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M7G4B57ZCB, chemically known as benzoic acid, 4-amino-2-butoxy-, 2-(diethylamino)ethyl ester but generally known as ambucaine, which bears US NIH Compound Identifier 8387. European Medicines Agency schedules Ambucaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05399MIG.

UNSPSC 51271902 Ambucaine, a Commodity code, covers local anesthetic pharmaceutical products that state and local governments procure through cooperative purchasing agreements and direct pharmaceutical supply contracts. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, actively solicits generic multi-source pharmaceuticals and OTC products under this category for distribution to participating state and local government facilities across multiple jurisdictions including Oregon. State procurement offices, health departments, and public health systems use this code to acquire pharmaceutical inventory through established wholesaler channels, with vendors required to maintain relationships with authorized distributors (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health, and Morris & Dickson Co., LLC), comply with current Good Manufacturing Practices and the Drug Supply Chain Security Act, and provide pricing in formats such as flat price, net price, or WAC-minus structures. Issuing bodies under this code include state cooperative purchasing entities like MMCAP and the jurisdictions participating in their alliances.

MMCAP issued a Request for Proposal (RFP) on January 20, 2026, with a response deadline of March 26, 2026, to establish multiple contracts for generic pharmaceuticals and OTC products effective July 1, 2026. The solicitation requires vendors to submit detailed product information including National Drug Codes, SKUs, UPCs, generic descriptions, strength, dosage form, packaging configurations, and manufacturing locations, with all products available in the marketplace by May 15, 2026. Evaluation is weighted heavily on price competitiveness (75 percent), with the remaining 25 percent distributed across fixed pricing compliance, administrative format requirements, EDI capability, and acceptance of a 3 percent administrative fee. Contract terms are two years for new vendors with optional extensions at MMCAP's discretion, and vendors must maintain comprehensive insurance coverage including $5 million commercial general liability per occurrence, $2 million network security and privacy liability, and $2 million professional liability.